Abstract
There is extensive evidence that changes in immune system activation accompany the pathological changes of Alzheimers disease (AD), but a mechanistic understanding of how the immune system actually participates in disease pathogenesis is still largely lacking. Because of the complexity of the immunological response, and the difficulty in identifying the key molecular players that underlie any given immunological response, expanding our understanding of the immunological response in AD beyond its descriptive stages has not been a straightforward exercise. The development of transgenic animals that form deposits of Aβ peptide in their brains has provided an unexpected dividend to those interested in the immunological response characterizing AD. Several of these transgenic models develop structures greatly resembling neuritic plaques, a hallmark feature of AD brain that is also a focal point of the immunological response occurring in AD. Genetic and pharmacological manipulation of these Aβ-depositing transgenic mice is providing some intriguing and unexpected insights into the role of innate and adaptive immune mechanisms in the pathogenesis of AD. This review will discuss immunological perspectives that have arisen from research using Aβ-depositing transgenic mice, and place these perspectives in the context of epidemiological and genetic studies that have previously suggested a role for the immune system in AD. The emerging story affirms the likely role of innate and adaptive immune mechanisms in the pathogenesis of AD, but provides a cautionary note as to the difficulties that are likely to face potential immunomodulatory therapies due to the dualistic beneficial and detrimental roles that immune mechanisms appear to play in AD.
Keywords: mhc-class II positive microglia, aging, nsaids, inflammatory response, amyloid angiopathy, immunomodulator
Current Pharmaceutical Design
Title: The Dualistic Nature of Immune Modulation In Alzheimers Disease: Lessons from the Transgenic Models
Volume: 11 Issue: 26
Author(s): R. B. Nelson
Affiliation:
Keywords: mhc-class II positive microglia, aging, nsaids, inflammatory response, amyloid angiopathy, immunomodulator
Abstract: There is extensive evidence that changes in immune system activation accompany the pathological changes of Alzheimers disease (AD), but a mechanistic understanding of how the immune system actually participates in disease pathogenesis is still largely lacking. Because of the complexity of the immunological response, and the difficulty in identifying the key molecular players that underlie any given immunological response, expanding our understanding of the immunological response in AD beyond its descriptive stages has not been a straightforward exercise. The development of transgenic animals that form deposits of Aβ peptide in their brains has provided an unexpected dividend to those interested in the immunological response characterizing AD. Several of these transgenic models develop structures greatly resembling neuritic plaques, a hallmark feature of AD brain that is also a focal point of the immunological response occurring in AD. Genetic and pharmacological manipulation of these Aβ-depositing transgenic mice is providing some intriguing and unexpected insights into the role of innate and adaptive immune mechanisms in the pathogenesis of AD. This review will discuss immunological perspectives that have arisen from research using Aβ-depositing transgenic mice, and place these perspectives in the context of epidemiological and genetic studies that have previously suggested a role for the immune system in AD. The emerging story affirms the likely role of innate and adaptive immune mechanisms in the pathogenesis of AD, but provides a cautionary note as to the difficulties that are likely to face potential immunomodulatory therapies due to the dualistic beneficial and detrimental roles that immune mechanisms appear to play in AD.
Export Options
About this article
Cite this article as:
Nelson B. R., The Dualistic Nature of Immune Modulation In Alzheimers Disease: Lessons from the Transgenic Models, Current Pharmaceutical Design 2005; 11 (26) . https://dx.doi.org/10.2174/138161205774370843
DOI https://dx.doi.org/10.2174/138161205774370843 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advancement in the Treatment of Cardiovascular Diseases: Conventional Therapy to Nanotechnology
Current Pharmaceutical Design Editorial (Hot Topic:Depression and Serotonin: A Never Ending Story)
Current Drug Targets Meet the Editorial Board:
CNS & Neurological Disorders - Drug Targets Bradykinin is Involved in the Mediation of Cardiac Nociception during Ischemia through Upper Thoracic Spinal Neurons
Current Neurovascular Research Potential Impact of Genetic Variants in Nrf2 Regulated Antioxidant Genes and Risk Prediction of Diabetes and Associated Cardiac Complications
Current Medicinal Chemistry Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy
Letters in Drug Design & Discovery Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Inhibitor at the Gates, Inhibitor in the Chamber: Allosteric and Competitive Inhibitors of the Proteasome as Prospective Drugs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Prevalence of Epilepsy in the Nakhichevan Autonomous Republic of Azerbaijan
CNS & Neurological Disorders - Drug Targets Effectiveness of Antiretroviral Therapy in HIV-1-Infected Active Drug Users Attended in a Drug Abuse Outpatient Treatment Facility Providing a Multidisciplinary Care Strategy
Current HIV Research Effect of Socio-Economic Factors on the Health Status of the Elderly
Applied Clinical Research, Clinical Trials and Regulatory Affairs Synthesis and Antibacterial and Antifungal Activity of 5-Substituted Imidazolones
Letters in Drug Design & Discovery A Study for Therapeutic Treatment against Parkinson’s Disease via Chou’s 5-steps Rule
Current Topics in Medicinal Chemistry Connecting the Brain and New Drug Targets for Schizophrenia
Current Pharmaceutical Design Schizophrenia and Liver Dysfunction Caused by Portacaval Shunting
Current Psychiatry Reviews Editorial [Hot Topic: G-Protein-Coupled Receptors (GPCRs) and Drug Discovery (Guest Editor: Luca Gentilucci)]
Current Drug Targets Analgesic and CNS Depressant Activities of Sea Anemone Heteractis aurora Nematocyst Toxin
Central Nervous System Agents in Medicinal Chemistry Death-Associated Protein Kinase 1 as a Promising Drug Target in Cancer and Alzheimer’s Disease
Recent Patents on Anti-Cancer Drug Discovery Editorial
Current Drug Metabolism Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design